Core Insights - The A-share market has shown an upward trend since 2025, leading to a general recovery in the performance of actively managed equity funds, with the total industry scale approaching a new high of 36 trillion [1][13] - Among 4,711 actively managed equity funds with performance records, 4,494 reported positive returns over the past year, while 217 had negative returns [1][13] - The top 30 funds with the largest declines all had annual returns below -9.75%, with several funds losing over 15%, including Huafu Medical Innovation A at -27.13% [1][14] Fund Performance - The worst-performing funds include: - Huafu Medical Innovation A: -27.13% return, size 0.60 billion [2][14] -浦银安盛医疗创新A: -20.29% return, size 0.16 billion [2][14] - 鑫元消费甄选A: -19.65% return, size 0.29 billion [2][14] - The performance of the top 30 funds with the largest declines indicates significant underperformance, with many funds experiencing substantial losses [1][15] Historical Performance Analysis - Dongwu Industry Rotation A and Dongwu Progress Strategy A, managed by Zhao Meiling, have shown poor performance, with returns of -12.66% and -10.90% respectively [3][15] - Both funds have long histories, with Dongwu Industry Rotation A established in April 2008 and Dongwu Progress Strategy A in May 2009, yet they have consistently underperformed in recent years [4][16] - The three-year returns for these funds are -22.25% and -24.34%, significantly lagging behind their benchmarks [4][16] Portfolio Composition - The two funds exhibit high similarity in their holdings, with overlapping top ten stocks that have generally performed poorly recently [5][17] - Key holdings for Dongwu Industry Rotation A include: - 分众传媒: 8.52% - 恒瑞医药: 6.94% - 圆通速递: 6.71% [19] - Recent performance of these stocks has been detrimental to the funds' net values, with significant declines observed [19] Industry Trends - Zhao Meiling's funds have a long-term focus on consumer, pharmaceutical, and high-end manufacturing sectors, which have shown mixed performance in recent structural market conditions [12][24] - The overall market for actively managed equity funds in 2025 has been positive, but significant internal differentiation exists, with some thematic products and smaller funds struggling amid market volatility [12][24]

Core Insights - The A-share market has shown an upward trend since 2025, leading to a general recovery in the performance of actively managed equity funds, with the total industry scale approaching a new high of 36 trillion yuan [1][14] - Among 4,711 actively managed equity funds with performance records, 4,494 reported positive returns, while 217 had negative returns over the past year [1][14] - Notably, the worst-performing funds had annual returns below -9.75%, with several losing over 15%, including Huafu Medical Innovation A at -27.13% [1][14] Fund Performance - The top three worst-performing funds included: - Huafu Medical Innovation A: -27.13% return, 0.60 billion yuan in size [2][15] -浦银安盛医疗创新A: -20.29% return, 0.16 billion yuan in size [2][15] - 鑫元消费甄选A: -19.65% return, 0.29 billion yuan in size [2][15] - Among the top 30 funds with the largest declines, six were managed by GF Fund under manager Wang Mingxu [1][14] Manager Performance - Wang Mingxu's managed funds have shown a significant decline in scale, dropping from a peak of 30.65 billion yuan in Q2 2021 to 8.26 billion yuan by Q4 2025, with six of his eight funds in the top 30 worst performers [4][17] - The funds managed by Wang exhibit a high degree of similarity in their holdings, leading to collective underperformance [10][23] Investment Strategy - Wang's flagship fund, GF Domestic Demand Growth A, experienced a significant style shift in 2025 but failed to improve performance, ending the year with a -16.31% return [5][18] - The fund's portfolio included heavyweights in the liquor, real estate, banking, and brokerage sectors, but the performance of these stocks was weak, with many declining over 10% [21][23] - Despite attempts to diversify into technology and manufacturing stocks, the overall results remained disappointing, indicating a mismatch between investment strategy and market conditions [13][23]

Core Insights - The A-share market has shown an upward trend since 2025, leading to a general recovery in the performance of actively managed equity funds, with the total industry scale approaching 36 trillion yuan [1][10] - Among 4,711 actively managed equity funds with performance records, 4,494 reported positive returns, while 217 had negative returns over the past year [1][10] - Over a three-year period, 924 out of 3,792 funds recorded negative returns, indicating a significant number of funds struggling to maintain performance [1][10] - The top 30 funds with the worst annual returns all had returns below -9.75%, with several funds losing over 15% [1][10] Fund Performance - The worst-performing fund, Huafu Medical Innovation A, had a return of -27.13%, followed by浦银安盛医疗创新A at -20.29% and 鑫元消费甄选A at -19.65% [2][11] - The performance of the top 30 funds with the largest declines highlights the challenges faced by certain actively managed funds in a fluctuating market [12][18] Specific Fund Analysis - 鑫元消费甄选A, managed by 姚启瑶, has shown particularly poor performance with a return of -19.85% since its inception in March 2023, resulting in a cumulative return of -49.37% [12][18] - The fund has experienced three changes in fund managers within a short period, which has led to challenges in maintaining a consistent investment strategy [13][18] - The current fund manager, 姚启璠, has a return of -2.41% since taking over in July 2025, with a focus on media and consumer sectors, but has faced challenges due to poor performance of key holdings [15][18] Market Trends - The overall market for actively managed equity funds has shown positive trends, but significant internal differentiation exists, with some thematic funds and smaller-scale funds struggling amid market volatility [18] - The ability to enhance flexibility in asset allocation and improve stock selection accuracy will be crucial for these funds to recover from their current low performance [18]

Group 1 - The annual report of public funds for 2025 shows significant performance, with the top fund, Yongying Technology Smart A, achieving a return of 233.29% and a scale of 11.52 billion [1][9] - The second and third positions are held by Zhonghang Opportunity Leading A with a return of 168.92% and Hongtu Innovation Emerging Industry A with a return of 148.64%, with scales of 13.23 billion and 14.86 billion respectively [1][9] - The total scale of public funds reached 35.89 trillion, an increase of 3.65 trillion from the beginning of the year, with a total of 13,610 funds [5][13] Group 2 - Looking ahead to 2026, the core theme of market opportunities is expected to be driven by AI-induced industrial transformation, with a focus on fundamental verification rather than liquidity-driven optimism [2][10] - The cloud computing sector is anticipated to see sustained growth in demand due to the acceleration of AI applications, alongside stable competition in core areas like optical communication and PCB [2][10] - The investment focus is shifting from AI hardware to application sectors, particularly in smart driving, AI hardware (such as AI phones and AR glasses), and humanoid robots [3][11] Group 3 - The performance of funds over the past three years shows Dongwu New Trend Value Line leading with a cumulative return of 273.85%, followed by Dongwu Mobile Internet A at 262.23% and Huaxia North Exchange Innovation Small and Medium Enterprises Selection at 260.42% [3][11] - The bottom performers include Huafu Medical Innovation A with a return of -26.15% and CITIC Construction Low Carbon Growth A with a return of -51.87% over three years [4][12] - The public fund market has experienced sharp performance differentiation amid macro narrative changes, highlighting the potential for high-quality growth in the coming years [8][15]

Group 1: Market Performance - The A-share market has shown strong performance this year, with the Shanghai Composite Index rising by 19.25%, the Shenzhen Component Index by 29.52%, and the ChiNext Index by 51.03% as of October 27 [1][2] - The Hang Seng Index and the Hang Seng Technology Index have also increased by 31.77% and 38.11% respectively [1] - Over 30 equity funds have doubled their returns this year, with some funds achieving over 100% returns [2] Group 2: Fund Performance and Strategy - The average return for over 1,000 ordinary stock funds is 31.21%, with a median return of 29.01% [2] - Notable funds like Yongying Technology Select A have reported a return of 206.10% year-to-date, while others like China Europe Digital Economy A have achieved 138.72% [3][4] - Fund managers are advising investors to diversify their investments to mitigate risks associated with high valuations in the AI sector [4] Group 3: Sector Insights - The technology sector, particularly companies involved in optical packaging, has been a significant contributor to fund performance [3] - The CPO index has seen a rise of over 100% this year, indicating strong growth in this segment [3] - The healthcare sector has shown mixed results, with some funds underperforming despite a previous uptrend in the medical index [5] Group 4: Fund Manager Insights - Fund managers are increasingly cautious about the high valuations in the AI sector, suggesting that some stocks may be overvalued based on optimistic growth expectations [4] - There is a call for a balanced approach in asset allocation, emphasizing the importance of not concentrating investments in a single sector [4][5] - The healthcare sector is undergoing a rationalization phase, with funds adjusting their portfolios to include a mix of innovative and generic drugs [5] Group 5: Research and Analysis Trends - Public funds are intensifying their research efforts during the earnings report season, with a significant increase in the number of companies being surveyed [6][7] - The pharmaceutical and biotechnology sectors are receiving the most attention from public fund managers, indicating a focus on validating company performance and growth potential [6][7]